IMR Press / RCM / Volume 2 / Issue S1 / pii/1561516080222-1523825430

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Clinical Experience with the Use of Fenoldopam for Prevention of Radiocontrast Nephropathy in High-Risk Patients
Show Less
1 St. Joseph's Medical Center, Stockton, CA
Rev. Cardiovasc. Med. 2001, 2(S1), 26–30;
Published: 20 January 2001
A protocol for using fenoldopam, an FDA-approved intravenous agent for the t reatment of severe hypertension with a newly available renal vasodilatory effect, was adopted to prevent radiocontrast nephropathy in high-risk patients undergoing angiographic procedures. Fenoldopam is a selective dopamine-receptor agonist with renoprotective properties. The results of 46 consecutive procedures were re t rospectively reviewed in both diabetic and nondiabetic patients and compare d to a prior published cohort of similarly at-risk patients. The incidence of radiocontrast nephropathy was 13% in the group treated with fenoldopam, compare d to an expected 38% based on historical controls. The percentage change in seru m c reatinine was also very favorable. In this clinical experience of a high-volume coronary and peripheral vascular laboratory, the use of fenoldopam in high-risk patients appeared to minimize the likelihood of radiocontrast nephropathy.
Radiocontrast nephropathy
Back to top